Correlation of disease activity with circulating immune complexes (C1qbA) and complement breakdown products (C3D) in patients with systemic lupus erythematosus. A prospective study.
Most biologic effects of immune complexes are mediated through the activation of the complement system. The relationship between lupus disease activity and the presence of C3 breakdown products (C3d) and circulating immune complexes (CIC) as demonstrated with the C1q binding assay (C1qbA), was evaluated. Nearly all 13 systemic lupus erythematosus (SLE) patients had a stable disease course in this prospective study, nevertheless, in each patient the profiles of the serologic parameters were quite different. Despite the small number of investigated patients (13), it is concluded that irrespective of the disease activity, the serologic parameters could be either positive or negative. No relationship could be obtained between disease activity and the presence of C3d and/or CIC. Nor was there any evidence that the presence of CIC would indicate increased levels of C3 breakdown products (C3d). This observation argues against a pathogenetic significance of CIC detected by the C1qbA in SLE. In conclusion, the supposed link between the presence of CIC, consumption and activation of the complement system, and the activity of SLE needs further study.
D000328:Adult; D000368:Aged; D000936:Antigen-Antibody Complex / Q000378:metabolism*; D003166:Complement Activating Enzymes; D003167:Complement Activation; D015922:Complement C1q; D003176:Complement C3 / Q000378:metabolism*; D015933:Complement C3d; D004247:DNA / Q000276:immunology; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000209:etiology / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D000936:Antigen-Antibody Complex; D003176:Complement C3; D015922:Complement C1q; D015933:Complement C3d; D004247:DNA; D003166:Complement Activating Enzymes